Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PEBP1 |
| Gene Name: | PEBP1 |
| Protein Full Name: | Phosphatidylethanolamine-binding protein 1 |
| Alias: | 23 kDa morphine-binding protein; B-RAF proto-oncogene serine/threonine-protein kinase; HCNP; Hippocampal cholinergic neurostimulating peptide; Neuropolypeptide h3; P23K; PBP; PEBP; Phosphatidylethanolamine binding protein 1; Phosphatidylethanolamine-binding protein; Prostatic-binding protein; Raf kinase inhibitor protein; Raf kinase inhibitory protein |
| Mass (Da): | 21057 |
| Number AA: | 187 |
| UniProt ID: | P30086 |
| Locus ID: | 5037 |
| COSMIC ID: | PEBP1 |
| Gene location on chromosome: | 12q24.23 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20269 |
| Percent of cancer specimens with mutations: | 0 |
| Normal role description: | Inhibits MEK/ERK pathway as well as RAF and GRK2. May promote apoptosis through inhibition of the NF-kB pathway. PEBP1 levels decrease in many cancer systems leading to increased MEK/ERK signalling and cell survival. |